Nanogen Seeks Buyer for Microarray Business As It Focuses on Other MDx, PoC Technologies

Nanogen cited the drain on its financials and the slow pace at which multiplex molecular diagnostics, such as those being developed on its NanoChip 400 instrument, have been adopted by the healthcare market as primary reasons for its decision.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.